WeVote
Log In

Bill

Bill

HB 5430

Relating to pharmaceutical benefits

2026 Regular Session Introduced by Mickey Petitto and 1 co-sponsor

HB 5430 aims to regulate pharmaceutical benefits to improve affordability, transparency, and consumer protections in pricing, access, and formulary decisions.

Approved by Governor 4/1/2026
#humanservices
0
WeVote Research Nonpartisan
Bill Summary · HB 5430

Summary of HB 5430 (2026) – West Virginia

Relating to pharmaceutical benefits

This summary outlines the primary purpose, key provisions, affected parties, and procedural timelines associated with HB 5430 from the 2026 West Virginia legislative session. The analysis focuses on the substantive elements and potential impact of the bill.

1) Purpose and intent

  • Purpose: To regulate and govern certain aspects of pharmaceutical benefits within the state. The bill appears to address how pharmaceutical benefits are managed, possibly including pricing, access, transparency, or cost-control measures within state programs, private plans, or a combination of both.
  • Intent: Improve affordability, transparency, and accountability in the administration of pharmaceutical benefits; enhance consumer protections related to drug pricing and access.

Note: The exact language of the bill would specify the precise policy goals (e.g., public program alignment, drug price transparency, or oversight mechanisms). This summary reflects the general aim to reform or regulate pharmaceutical benefits.

2) Key provisions and changes (provisions may include, but are not limited to)

  • Pricing and cost-control measures: Provisions that may set or influence the prices of pharmaceuticals, negotiate discounts, or cap out-of-pocket costs for certain drugs or populations.
  • Transparency requirements: Requirements for issuers, pharmacy benefit managers (PBMs), or health plans to disclose pricing, rebates, ingredient costs, or formulary decisions.
  • Formulary and coverage rules: Rules governing what drugs must be covered, prior authorization processes, step therapy, or formulary placement to improve access or reduce costs.
  • Program oversight and governance: Creation or empowerment of a state body, board, or agency to administer and enforce pharmaceutical benefit provisions; reporting and auditing requirements.
  • Consumer protections: Provisions aimed at protecting consumers from surprise charges, discriminatory practices, or denial of coverage for medically necessary medications.
  • Implementation timeline: Schedule for phased implementation, effective dates for new requirements, and any transition periods for plans or programs to comply.

Because the bill’s exact text is not provided, the above categories reflect common elements found in pharmaceutical-benefits legislation. The precise provisions, their scope, and any exemptions would be stated in the bill’s text.

3) Who would be affected

  • State programs and agencies: If the bill creates or modifies state-level programs or oversight, relevant agencies (e.g., Health and Human Resources, insurance, or budget offices) would implement and enforce changes.
  • Health insurers and plans: Private and public health plans operating in West Virginia, including employer-sponsored plans, would need to comply with new pricing, transparency, and formulary requirements.
  • Pharmacy Benefit Managers (PBMs): If the bill addresses PBM practices (discounts, rebates, or pass-through pricing), PBMs would be subject to reporting and operational rules.
  • Drug manufacturers and pharmacies: Depending on compliance obligations and disclosure requirements, manufacturers and pharmacies could face new reporting duties, formulary constraints, or price-communication requirements.
  • Consumers and patients: End-users could experience changes in out-of-pocket costs, access to medications, and transparency around drug pricing.

4) Procedural and timeline aspects

  • Legislative process: As with other West Virginia bills, HB 5430 would go through committee hearings, potential amendments, and floor votes in both chambers before being sent to the governor for signature or veto.
  • Effective dates: The bill may establish an effective date for its provisions, with some sections taking effect immediately and others after a defined period (e.g., 6–12 months) to allow for implementation.
  • Reporting requirements: If applicable, the bill could require annual or periodic reporting on pricing, cost savings, or program effectiveness to the Legislature or a state agency.

5) Potential implications and considerations

  • Cost containment vs. access: The balance between reducing drug costs and ensuring patient access to necessary medications.
  • Market impact: Possible effects on PBM operations, formulary design, and negotiations with manufacturers.
  • Administrative burden: Compliance costs for insurers, plans, and providers; need for robust data collection and reporting systems.
  • Legal considerations: Alignment with federal law and existing state regulations governing health benefits and pharmaceutical pricing.

If you can provide the official text or key excerpts from HB 5430, I can tailor this summary with precise provisions, statutory references, dates, and any numeric thresholds or deadlines.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.